-
Deutsche Bank Reiterates Hold On XenoPort (XNPT)
Thursday, February 17, 2011 - 8:16am | 118Deutsche Bank is reiterating its Hold rating and $8 price target on shares of XenoPort (NASDAQ: XNPT). In a note to clients, Deutsche Bank writes, "While XenoPort and partner GSK now have an FDA action date for Horizant and a sound strategy for obtaining final approval, we continue to think that...
-
Top 4 NASDAQ Stocks In The Drugs-Generic Industry With The Highest Cash (MYL, SLXP, HITK, AKRX)
Thursday, February 17, 2011 - 4:11am | 137Below are the top drugs-generic stocks on the NASDAQ in terms of cash. Mylan Inc (NASDAQ: MYL) had $641.03 million in total cash for the latest quarter. Meanwhile, MYL's total debt stood at $5.41 billion. Salix Pharmaceuticals Ltd (NASDAQ: SLXP) had $491.47 million in total cash and $319.99 million...
-
FOMC Minutes Optimistic 02-16-2011
Wednesday, February 16, 2011 - 7:43pm | 902Cusick's Corner The S&P 500 has now doubled its value from two years ago and the tone of the overall market remains upbeat. Corporate earnings are staying positive. The FOMC Minutes that were released today sounded more optimistic about the nation's recovery; however they were not satisfied...
-
Data Points to Inflation 02-16-2011
Wednesday, February 16, 2011 - 7:42pm | 956Cusick's Corner Inflation. The market this morning seems to think that inflation may be coming faster than originally anticipated. This was reflected in the PPI numbers that came in shockingly high, mostly due to commodity inflation. This puts further constraints on the consumer and whether or not...
-
XenoPort Reports Q4 EPS of $(0.47) vs. $(0.62)
Wednesday, February 16, 2011 - 5:13pm | 73XenoPort, Inc. (Nasdaq: XNPT) announced today its financial results for the fourth quarter and year ended December 31, 2010. Revenues for the quarter were $1.9 million, compared to $5.8 million for the same period in 2009. Net loss for the fourth quarter was $14.8 million, compared to a net loss...
-
First Patient Enrolled in Second Phase III Clinical Trial of Urocidin
Wednesday, February 16, 2011 - 5:10pm | 117Endo Pharmaceuticals (Nasdaq: ENDP) and Bioniche Life Sciences Inc. (TSX and ASX: BNC), today announced enrollment of the first patient in the second Phase III clinical trial of Urocidin™. The trial is a randomized, active-controlled, open-label, multi-center study with a blinded endpoint...
-
Endo Pharmaceuticals Announces First Patient Enrolled in Second Phase III Clinical Trial of Urocidin
Wednesday, February 16, 2011 - 5:05pm | 68Endo Pharmaceuticals (Nasdaq: ENDP) and Bioniche Life Sciences Inc., today announced enrollment of the first patient in the second Phase III clinical trial of Urocidin. The trial is a randomized, active-controlled, open-label, multi-center study with a blinded endpoint assessment designed to...
-
Unconfirmed Rumors circulate that Novartis AG (NVS) Is in talks with Star Scientific, Inc. (CIGX) on a major Joint Venture.Would be huge positive for (CIGX).
Wednesday, February 16, 2011 - 12:50pm | 47Unconfirmed Rumors circulate that Novartis AG (NVS) Is in talks with Star Scientific, Inc. (CIGX) on a major Joint Venture.Would be huge positive for (CIGX).
-
Optimer Pharmaceuticals, Inc. Announces Closing of $77.6M Offering
Wednesday, February 16, 2011 - 12:19pm | 79Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced the completion of a public offering of 6,900,000 shares of its common stock, including 900,000 shares sold pursuant to the full exercise of an overallotment option previously granted to the underwriters. The shares were sold at a public...
-
Benzinga's Volume Movers (GENZ, ELOS, KNXA, DELL)
Wednesday, February 16, 2011 - 11:32am | 165Genzyme Corporation (NASDAQ: GENZ) shares moved up 1.57% to $75.47 at 10:30 am. The volume of GENZ shares traded was 1854% higher than normal. Sanofi-Aventis SA (NYSE: SNY) has agreed to purchase GENZ for around $20.1 billion in cash. Syneron Medical Ltd (NASDAQ: ELOS) shares rose 17.72% to $13.75...
-
NASDAQ Stocks Hitting 52-Week Highs (LINTA, GENZ, CMCSA, ASMI)
Wednesday, February 16, 2011 - 11:22am | 153Liberty Media Corporation (NASDAQ: LINTA) shares gained 1.00% to create a new 52-week high of $17.20. LINTA shares have surged 54.82% over the past 52 weeks, while the S&P 500 index has gained 21.29% in the same period. Genzyme Corporation (NASDAQ: GENZ) shares rose 1.62% to touch a new 52-week...
-
Morning Market Movers (CYAN, FDO, RCKY, LZB)
Wednesday, February 16, 2011 - 11:01am | 129Cyanotech Corporation (NASDAQ: CYAN) gained 65.27% to $4.33 at 10:00 am. University of California Davis research study indicated that CYAN's Spirulina Pacifica may improve immune function and ameliorate anemia in persons over age 50. Family Dollar Stores Inc (NYSE: FDO) shares surged 24.20% to $54...
-
Discovery Laboratories to Resume Trading at 9.40 am
Wednesday, February 16, 2011 - 10:36am | 17Discovery Laboratories (NASDAQ: DSCO) to Resume Trading at 9.40 am.
-
Discovery Labs Prices $23.5 Million Public Offering
Wednesday, February 16, 2011 - 10:13am | 175Discovery Laboratories, Inc. (Nasdaq: DSCO) today announced that it has priced an underwritten public offering of 10,000,000 units at a price to the public of $2.35 per unit for gross proceeds of $23.5 million. Each unit consists of one share of common stock, a five-year warrant to purchase 0.50...
-
Trading Halted: Discovery Laboratories
Wednesday, February 16, 2011 - 10:12am | 14Trading Halted: Discovery Laboratories (NASDAQ: DSCO)